Literature DB >> 11287509

Determinants of postembolization syndrome after hepatic chemoembolization.

D A Leung1, J E Goin, C Sickles, B J Raskay, M C Soulen.   

Abstract

PURPOSE: Postembolization syndrome (PES) occurs in the majority of patients undergoing hepatic chemoembolization, and is the major reason for hospitalization after the procedure. The ability to identify which groups of patients are at increased or decreased risk of PES would be useful to better counsel patients, to minimize toxicity, and to plan inpatient versus outpatient therapy.
MATERIALS AND METHODS: Seventy hepatic chemoembolization procedures were performed in 29 patients using cytotoxic drugs mixed with Ethiodol and polyvinyl alcohol. The following procedural variables were retrospectively assessed and evaluated for association with PES and length of postprocedural hospitalization: gallbladder embolization, lobe embolized, percentage liver volume embolized, percentage embolized volume occupied by tumor, previous embolization of the same territory, and dose of chemoembolic emulsion. Logistic regression was used to quantify the relative effect of each procedural variable.
RESULTS: Gallbladder embolization and dose administered were associated with an increased risk of PES and an extended hospitalization, with odds ratios of 2.8 and 3.0, and 3.0 and 4.6, respectively. Previous embolization was associated with a decreased risk of both PES and extended hospitalization, with odds ratios of 0.5 and 0.4, respectively. There was a statistical trend toward significance for gallbladder embolization (P = .06), dose administered (P = .07), and previous embolization (P = .14).
CONCLUSION: Clinically relevant predictors of the severity of PES and length of postprocedural hospitalization may exist. Avoiding embolization of the gallbladder reduces the risk of PES. Re-embolization of previously treated vessels is associated with decreased toxicity and may assist in selecting patients for treatment on an outpatient basis, especially when a reduced dose is required.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11287509     DOI: 10.1016/s1051-0443(07)61911-3

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  52 in total

1.  Hepatic transcatheter arterial chemoembolization complicated by postembolization syndrome.

Authors:  Sabeen Dhand; Ramona Gupta
Journal:  Semin Intervent Radiol       Date:  2011-06       Impact factor: 1.513

2.  Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort.

Authors:  Robert J Lewandowski; Mary F Mulcahy; Laura M Kulik; Ahsun Riaz; Robert K Ryu; Talia B Baker; Saad M Ibrahim; Michael I Abecassis; Frank H Miller; Kent T Sato; Seanthan Senthilnathan; Scott A Resnick; Edward Wang; Ramona Gupta; Richard Chen; Steven B Newman; Howard B Chrisman; Albert A Nemcek; Robert L Vogelzang; Reed A Omary; Al B Benson; Riad Salem
Journal:  Radiology       Date:  2010-06       Impact factor: 11.105

3.  Complications of hepatic chemoembolization.

Authors:  Timothy W I Clark
Journal:  Semin Intervent Radiol       Date:  2006-06       Impact factor: 1.513

4.  Survival rates according to barcelona clinic liver cancer sub-staging system after transarterial embolization for intermediate hepatocellular carcinoma.

Authors:  Leandro Armani Scaffaro; Steffan Frosi Stella; Mario Reis Alvares-Da-Silva; Cleber Dario Pinto Kruel
Journal:  World J Hepatol       Date:  2015-03-27

Review 5.  Prevention and management of infectious complications of percutaneous interventions.

Authors:  Steven Y Huang; Asher Philip; Michael D Richter; Sanjay Gupta; Mark L Lessne; Charles Y Kim
Journal:  Semin Intervent Radiol       Date:  2015-06       Impact factor: 1.513

Review 6.  Role of Transcatheter Intra-arterial Therapies for Hepatocellular Carcinoma.

Authors:  Shashi B Paul; Hanish Sharma
Journal:  J Clin Exp Hepatol       Date:  2014-05-24

7.  Prevention of post-embolization syndrome after transarterial chemoembolization for hepatocellular carcinoma-is prophylactic dexamethasone useful, or not?

Authors:  Toru Ishikawa
Journal:  Hepatobiliary Surg Nutr       Date:  2018-06       Impact factor: 7.293

8.  Transarterial hepatic chemoembolization with 70-150 µm drug-eluting beads: assessment of clinical safety and liver toxicity profile.

Authors:  Bruno C Odisio; Aaron Ashton; Yuanqing Yan; Wei Wei; Ahmed Kaseb; Michael J Wallace; Jean N Vauthey; Sanjay Gupta; Alda L Tam
Journal:  J Vasc Interv Radiol       Date:  2015-06-05       Impact factor: 3.464

9.  Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States.

Authors:  Diane K Reyes; Josephina A Vossen; Ihab R Kamel; Nilofer S Azad; Tamara A Wahlin; Michael S Torbenson; Michael A Choti; Jean-Francois H Geschwind
Journal:  Cancer J       Date:  2009 Nov-Dec       Impact factor: 3.360

10.  Clinical factors associated with dense and wedge-shaped nephrograms detected 24 h after chemoembolization.

Authors:  Wayne L Monsky; Anokh Pahwa; Chin-Shang Li; Richard W Katzberg
Journal:  Cardiovasc Intervent Radiol       Date:  2009-11       Impact factor: 2.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.